![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Astellas Subsidiary Xyphos and GO Therapeutics Ink Deal Worth More Than $763 Million
Astellas Subsidiary Xyphos and GO Therapeutics Ink Deal Worth More Than $763 Million
June 2, 2022
Astellas Pharma subsidiary Xyphos Biosciences and GO Therapeutics have entered into a research and licensing agreement to develop novel antibodies for immuno-oncology therapies.
Under the agreement, the companies will select two novel antibodies using GO Therapeutics’ platform-based approach for targeting cancer-specific glycoproteins.
Xyphos will bring its CAR T-cell know-how to the collaboration. The company’s proprietary convertibleCAR technology creates cell therapies that can mobilize immune cells to find and destroy target tumor cells.
Xyphos will pay GO Therapeutics $20.5 million upfront in cash, plus potential milestone payments of up to $763 million.
Upcoming Events
-
21Oct